Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1639324-58-5
Molecular formula
C529H681F12N176O316P43S6
Molecular weight
17284.72 g/mol
Drug class
Small interfering RNA (siRNA) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA
Mechanism of action
A GalNAc-conjugated double-stranded siRNA is taken up by hepatocytes and directs RNA-induced silencing complex (RISC)-mediated degradation of PCSK9 mRNA, reducing hepatic PCSK9 protein and increasing LDL-receptor recycling and LDL-cholesterol clearance.
Indications / reported uses
Adjunct to diet and exercise to reduce LDL-cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease, under the applicable product label
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Inclisiran Environmental Risk Assessment (ERA) (the Inclisiran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.